Navigation Links
Standard Heart Drugs Won't Ease Pulmonary Hypertension
Date:5/18/2011

WEDNESDAY, May 18 (HealthDay News) -- Although commonly used to treat heart disease, aspirin and simvastatin offer no benefit to patients suffering from pulmonary arterial hypertension, or PAH, a progressive disease characterized by increased blood pressure in the arteries of the lungs, according to new research.

In a study funded by the U.S. National Institutes of Health, researchers divided 65 patients into four groups: one receiving aspirin; one taking simvastatin; one receiving both drugs; and one in which patients received a placebo (or dummy pill).

"Surprisingly, we found no evidence that aspirin or simvastatin had beneficial clinical effects in this population," said Dr. Steven Kawut, study lead author and associate professor of medicine and epidemiology at the University of Pennsylvania School of Medicine.

After taking the assigned medication for six months, patients were asked to see how far they could walk in six minutes. The distance tended to be shorter in the simvastatin group, and no difference was seen between the aspirin and placebo patients.

Following these early results, the U.S. National Heart, Lung, and Blood Institute discontinued the study based on a recommendation from the Data and Safety Monitoring Board.

"The results of this study do not support the routine treatment of PAH with these medications," Kawut said in an American Thoracic Society news release.

The findings are scheduled to be presented Wednesday at the American Thoracic Society international conference in Denver.

PAH, which is incurable, causes shortness of breath, dizziness and fatigue, and can lead to heart failure and death.

The researchers concluded that both aspirin and simvastatin may be prescribed for usual clinical indications in patients with PAH, but should not be administered specifically to treat PAH.

"The findings show the importance of subjecting traditional cardiovascular therapies and drugs which appear effective in the laboratory to placebo-controlled [randomized clinical trials] in humans before recommending their use," Kawut said.

Research presented at meetings is considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Heart, Lung, and Blood Institute provides more information on treatments for pulmonary arterial hypertension.

-- Mary Elizabeth Dallas

SOURCE: American Thoracic Society, news release, May 18, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. eHealthObjects chooses Elsevier/Gold Standard drug database
2. Human Factors/Ergonomics research leads to improved bunk bed safety standards
3. IOM recommends standards to achieve reliable clinical practice guidelines
4. Quality standards for widely used medicines strengthened
5. Federal Supply Schedule pricing added to ProspectoRx from Elsevier/Gold Standard
6. Standard Exams Might Not Catch Full Potential of Brain Damaged Patients
7. Community oncology: Ensuring the best standards of care
8. FDA Panel Recommends Tougher Standards for External Defibrillators
9. FDA Looking at Tougher Standards for External Defibrillators
10. FDA Looking for Tougher Standards for External Defibrillators
11. Universal standards proposed for prescription container labels to help reduce medication misuse
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Standard Heart Drugs Won't Ease Pulmonary Hypertension
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: